Skin Health & Treatment

Dog Skin Infections That Won't Go Away: Resistant Bacteria

By Emiel Maddens · Reviewed in consultation with licensed veterinary professionals · Updated June 2026 · 10 min read

Dog Skin Infections That Won't Go Away guide for dog owners

Key Takeaways

Antibiotic-resistant skin infections in dogs are increasing in frequency, driven by overuse of empirical antibiotics without culture guidance.
Biofilms, structured bacterial communities encased in a protective matrix, explain why some infections persist despite appropriate antibiotic selection.
Culture and sensitivity testing should be performed on any skin infection that fails to respond to first-line antibiotic therapy within two to three weeks.
Topical antiseptics, particularly chlorhexidine, remain effective against most resistant bacteria because their mechanism of action is difficult for bacteria to evade.
Identifying and controlling the underlying cause, such as allergies, endocrine disease, or immune dysfunction, is essential for preventing recurrence.

Few things are more frustrating for dog owners than a skin infection that simply will not go away. You follow the veterinarian's instructions, give the antibiotics on schedule, keep the area clean, and the infection improves temporarily, only to return within weeks of stopping treatment. This pattern of recurrent or persistent skin infection affects a growing number of dogs, and antibiotic resistance is frequently part of the explanation.

The rise of antibiotic-resistant bacteria in veterinary medicine mirrors the crisis in human health care. Staphylococcus pseudintermedius, the bacterium responsible for most canine skin infections, has developed resistance to multiple antibiotic classes at alarming rates. Methicillin-resistant S. pseudintermedius (MRSP) is now identified in 10 to 30 percent of canine pyoderma cases in some referral populations. Beyond resistance, bacterial biofilms, physical barriers that shield bacteria from both antibiotics and the immune system, contribute to treatment failure in ways that standard cultures may not reveal.

This article explains why some dog skin infections resist conventional treatment, outlines the diagnostic approach needed to identify the problem, and details the treatment strategies, including topical alternatives, that can overcome resistant infections.

Understanding Antibiotic Resistance in Canine Skin Bacteria

How Resistance Develops

Antibiotic resistance develops through genetic mutations and horizontal gene transfer between bacteria. Each time a dog receives antibiotics, the drug kills susceptible bacteria while leaving resistant ones to survive and multiply. Over repeated courses of antibiotics, particularly when courses are too short, doses too low, or the wrong antibiotic is chosen empirically, the proportion of resistant organisms in the population increases. Staphylococcus pseudintermedius is particularly adept at acquiring resistance genes, including the mecA gene that confers resistance to all beta-lactam antibiotics, including penicillins, cephalosporins, and carbapenems.

The Scope of the Problem

Studies from veterinary dermatology referral centers across North America and Europe have documented a steady increase in antibiotic resistance among canine skin pathogens over the past two decades. Resistance to first-line antibiotics including cephalexin, amoxicillin-clavulanate, and clindamycin now exceeds 20 percent in some populations. Multi-drug resistant strains, defined as resistant to three or more antibiotic classes, are identified in 5 to 15 percent of clinical isolates. These statistics underscore the importance of culture-guided antibiotic selection rather than empirical prescribing for anything beyond straightforward first-episode pyoderma.

Risk Factors for Resistant Infections

Several factors increase a dog's risk of developing an antibiotic-resistant skin infection. Prior antibiotic exposure, especially repeated or prolonged courses, is the single strongest risk factor. Hospitalization or frequent veterinary visits increase exposure to resistant organisms in the clinical environment. Underlying conditions that require immunosuppressive therapy, chronic skin disease requiring repeated antibiotic courses, and contact with other animals carrying resistant bacteria all elevate risk. Dogs that have received multiple antibiotic courses for recurrent pyoderma without culture guidance are at particularly high risk.

Biofilms: The Hidden Barrier to Treatment

What Are Biofilms?

Biofilms are structured communities of bacteria embedded in a self-produced extracellular matrix composed of polysaccharides, proteins, and DNA. Unlike free-floating planktonic bacteria, biofilm bacteria are phenotypically distinct and dramatically more resistant to both antibiotics and host immune defenses. The biofilm matrix physically blocks antibiotic penetration, and bacteria within the biofilm can be 100 to 1,000 times more resistant to antibiotics than the same organism growing planktonically. Biofilm formation has been demonstrated in canine skin infections, particularly in chronic, recurrent, or deep pyoderma.

How Biofilms Contribute to Treatment Failure

A skin infection containing biofilm-forming bacteria may show initial improvement with antibiotics, as the planktonic bacteria in the lesion are killed. However, the biofilm-embedded bacteria persist, serving as a protected reservoir that repopulates the infection site once antibiotic therapy ends. Standard culture and sensitivity testing evaluates only planktonic bacteria, so the culture may show susceptibility to the prescribed antibiotic even though the biofilm bacteria are effectively untreatable with that drug at achievable tissue concentrations. This disconnect explains the common clinical pattern of temporary improvement followed by relapse.

Disrupting Biofilms

Biofilm disruption requires a different approach than standard antibiotic therapy. Physical disruption through wound debridement, hydro-therapy, and mechanical cleansing removes portions of the biofilm matrix. Topical antiseptics, particularly chlorhexidine, have demonstrated anti-biofilm activity that systemic antibiotics lack. Chlorhexidine disrupts the biofilm matrix and kills bacteria within the biofilm at concentrations achievable with topical application. N-acetylcysteine and EDTA have shown in vitro biofilm-disrupting activity and may serve as adjunctive agents. Combining systemic antibiotics with aggressive topical therapy and mechanical disruption provides the best chance of overcoming biofilm-associated infections.

Dog Skin Infections That Won't Go Away veterinary guide

Diagnostic Approach to Non-Healing Infections

When to Perform Culture and Sensitivity Testing

Culture and sensitivity testing should be performed on any skin infection that fails to respond to appropriate first-line antibiotic therapy within 14 to 21 days, any infection that recurs within one month of completing antibiotic therapy, any deep pyoderma or furunculosis at initial presentation, and any infection in a dog with known prior exposure to resistant organisms. The test involves collecting samples from the active infection site, either by swab from an intact pustule or by tissue biopsy for deep infections, and submitting them to a diagnostic laboratory for bacterial identification and antibiotic susceptibility testing.

Interpreting Culture Results

Culture results report which bacteria were isolated and which antibiotics they are susceptible, intermediate, or resistant to. It is important to understand that in vitro susceptibility does not guarantee clinical efficacy, and in vitro resistance does not always mean clinical failure. Tissue concentrations, biofilm presence, and local factors all influence the outcome. When MRSP or other multi-drug resistant organisms are identified, treatment options may be limited to drugs such as chloramphenicol, rifampin, doxycycline, or amikacin, all of which carry their own side effect profiles. Close collaboration between the veterinarian and a veterinary dermatologist is advisable for multi-drug resistant cases.

Ruling Out Underlying Causes

A non-healing skin infection should always prompt investigation into why the infection persists. The most common underlying causes include uncontrolled allergic disease that continuously damages the skin barrier, endocrine diseases such as hypothyroidism or Cushing's disease that impair immune function, immunosuppressive medications, conformational factors such as deep skin folds that create anaerobic microenvironments, and foreign bodies that serve as a nidus for persistent infection. Addressing the underlying cause is just as important as selecting the right antibiotic; without it, the infection will recur regardless of which drug is used.

Advanced Diagnostics

In refractory cases, advanced diagnostics may be needed. Skin biopsies evaluated by a dermatopathologist can identify unusual infections such as mycobacteriosis, deep fungal infections, or sterile conditions that mimic infection. Special stains including PAS and GMS reveal fungal organisms that may be missed on routine histopathology. In rare cases, tissue culture for mycobacteria or atypical pathogens is needed. Imaging studies may identify foreign bodies, draining tracts, or deep tissue involvement that is not apparent on surface examination.

Topical Alternatives to Systemic Antibiotics

Chlorhexidine as a First-Line Topical Agent

Chlorhexidine is a broad-spectrum antiseptic that kills bacteria by disrupting cell membrane integrity. Because this mechanism is fundamentally different from how antibiotics work, bacteria have extreme difficulty developing resistance to chlorhexidine. Even MRSP strains that are resistant to every commonly used systemic antibiotic remain susceptible to chlorhexidine at clinically achievable concentrations. Chlorhexidine spray applied directly to infected skin two to three times daily is effective as monotherapy for superficial pyoderma and as adjunctive therapy for deeper infections. Multiple studies have demonstrated that topical chlorhexidine produces clinical outcomes equivalent to systemic antibiotics for localized, superficial pyoderma.

Medicated Shampoo Therapy

For dogs with widespread superficial pyoderma, medicated shampoo therapy with chlorhexidine at 2 to 4 percent concentration provides whole-body antimicrobial coverage. The shampoo should be lathered onto the skin and left in contact for a minimum of 10 minutes before rinsing to allow adequate antimicrobial activity. Twice-weekly bathing during active infection, transitioning to weekly maintenance bathing once the infection resolves, is a standard protocol. Shampoo therapy is particularly valuable for dogs with resistant infections because it addresses the entire skin surface without systemic antibiotic use.

When Systemic Antibiotics Are Still Necessary

Topical therapy alone is not sufficient for deep pyoderma, furunculosis, cellulitis, or widespread infections with systemic signs such as fever, lethargy, or lymphadenopathy. In these cases, culture-guided systemic antibiotics are essential, and the duration of therapy is typically four to six weeks or two weeks beyond clinical resolution, whichever is longer. Even when systemic antibiotics are needed, concurrent topical antiseptic therapy accelerates resolution and may allow a shorter total antibiotic course, reducing the selection pressure that drives further resistance development.

Preventing Antibiotic Resistance

Antibiotic Stewardship in Veterinary Medicine

Responsible antibiotic use is the most effective strategy for slowing the development of resistance. This means prescribing antibiotics only when a bacterial infection is confirmed, not for viral, fungal, or sterile conditions. It means selecting narrow-spectrum antibiotics as first-line agents, reserving broad-spectrum and last-resort antibiotics for culture-confirmed resistant infections. It means prescribing appropriate doses for adequate durations, not shortening courses when the dog looks better, and not extending them unnecessarily. Veterinary professional organizations including the ISCAID (International Society for Companion Animal Infectious Diseases) have published detailed antimicrobial use guidelines for practitioners.

The Role of Topical-First Approaches

Adopting a topical-first approach for superficial skin infections represents a paradigm shift in veterinary dermatology that directly reduces antibiotic consumption. For localized superficial pyoderma, topical chlorhexidine therapy as monotherapy is now recommended by multiple expert guidelines as a first-line treatment, with systemic antibiotics reserved for cases that fail topical therapy or that present with deep or widespread infection. This approach has been shown to produce equivalent clinical outcomes while dramatically reducing antibiotic use, with one study reporting a 75 percent reduction in systemic antibiotic prescriptions after implementing topical-first protocols.

Owner Education and Compliance

Dog owners play a critical role in preventing antibiotic resistance. Understanding why the entire course of antibiotics must be completed, why leftover antibiotics should never be used without veterinary guidance, and why culture testing is important for recurrent infections empowers owners to be active participants in antimicrobial stewardship. Owners should also understand that requesting antibiotics for every skin problem is counterproductive, and that topical treatments, while requiring more frequent application, ultimately produce better long-term outcomes by preserving antibiotic efficacy.

Working with Your Veterinarian on Resistant Infections

Communicating Treatment History

When seeking veterinary care for a non-healing skin infection, provide a complete history of all previous antibiotic treatments, including the drug name, dose, duration, and response. This information helps the veterinarian assess the likelihood of resistance and guides antibiotic selection. If culture results from previous infections are available, bring them to the appointment. A detailed treatment history is the single most useful piece of information for managing a resistant infection.

Setting Realistic Expectations

Resistant skin infections take longer to resolve than susceptible ones, and the treatment may be more complex, involving multiple topical products, extended antibiotic courses, and more frequent veterinary rechecks. Owners should be prepared for a multi-week treatment period and understand that managing the underlying cause is essential for preventing recurrence. Complete eradication of resistant organisms from the skin may not be possible; the realistic goal is to control infection and restore the skin barrier to a state where the immune system can manage the normal microbial population.

When to Seek Specialist Referral

Referral to a board-certified veterinary dermatologist is recommended for any multi-drug resistant infection, any deep pyoderma that fails to respond to culture-guided therapy, any infection associated with an unidentified underlying cause, and any case requiring antibiotics from the critically important or last-resort categories. Dermatologists have specialized experience with resistant infections, access to advanced diagnostics, and established relationships with reference laboratories that can guide complex antimicrobial decisions.

Fighting a stubborn skin infection?

Topical antiseptics remain effective when antibiotics fail. Our Chlorhexidine Spray disrupts bacterial cell membranes and biofilms through a mechanism that resistant bacteria cannot easily evade. FDA-registered and vet-formulated for safe daily use.

Shop Chlorhexidine Spray

Dog Skin Infections That Won't Go Away FAQ

Q: Why won't my dog's skin infection go away with antibiotics?

The most common reasons are antibiotic resistance, biofilm formation, an uncontrolled underlying condition that keeps damaging the skin barrier, or an incorrect diagnosis. Culture and sensitivity testing identifies resistance, while a thorough workup including cytology, blood work, and allergy assessment addresses the underlying cause.

Q: What is MRSP in dogs?

MRSP stands for methicillin-resistant Staphylococcus pseudintermedius. It is a strain of the most common canine skin bacterium that has acquired the mecA gene, making it resistant to all beta-lactam antibiotics including cephalosporins and penicillins. MRSP often carries resistance to multiple additional antibiotic classes, significantly limiting treatment options. It is now identified in 10 to 30 percent of canine pyoderma cases at referral centers.

Q: Can chlorhexidine kill resistant bacteria?

Yes. Chlorhexidine kills bacteria by disrupting cell membrane integrity, a mechanism that is fundamentally different from how antibiotics work. Because of this different mechanism, even multi-drug resistant strains including MRSP remain susceptible to chlorhexidine at clinically achievable concentrations. This makes chlorhexidine-based topical products an essential tool for managing resistant infections.

Q: Should every skin infection be cultured?

Not necessarily. First-episode, uncomplicated superficial pyoderma can be treated empirically with first-line antibiotics or topical therapy. However, culture and sensitivity testing is recommended for any infection that fails to respond to initial therapy, any recurrent infection, any deep pyoderma, and any infection in a dog with known prior resistant organisms. The test is relatively inexpensive and provides invaluable guidance for treatment.

Q: Can my dog spread resistant bacteria to me or other pets?

Yes, transmission of resistant Staphylococcus pseudintermedius between dogs and between dogs and humans has been documented, although it is relatively uncommon. The risk is highest in households with immunocompromised individuals. Good hygiene including hand washing after handling infected areas, avoiding direct contact with lesions, and washing contaminated bedding separately reduces transmission risk.

Sources

Morris, D.O., et al. (2017). Recommendations for approaches to meticillin-resistant staphylococcal infections of small animals. Veterinary Dermatology, 28(3), 304-e69.

Hillier, A., et al. (2014). Guidelines for the diagnosis and antimicrobial therapy of canine superficial bacterial folliculitis. Veterinary Dermatology, 25(3), 163-e43.

Bryan, J., et al. (2012). Antimicrobial activity of chlorhexidine against staphylococcal isolates from clinical cases in dogs and cats. Irish Veterinary Journal, 65, 10.

Frank, L.A., & Loeffler, A. (2012). Meticillin-resistant Staphylococcus pseudintermedius: clinical challenge and treatment options. Veterinary Dermatology, 23(4), 283-291.

Beco, L., et al. (2013). Suggested guidelines for using systemic antimicrobials in bacterial skin infections: part 2. Veterinary Record, 172(6), 156-160.

Account

Your cart is empty

Resistant Dog Skin Infections That Won't Heal